The article discusses research published in the September 2016 issue of the journal "Nature" on an antibody drug called aducanumab that have the potential to uncover the treatment for Alzheimer's disease. The study explained the amyloid hypothesis on Alzheimer's disease and assessed the cognitive benefits of the drugs for people with earl Alzheimer's disease. It examined the correlation between abnormal A-beta protein accumulation in the brain and damage to nerve cells.
No Comments.